Windlas Biotech Limited (WINDLAS) Fair Value & Analysis
Healthcare · IN · Market cap ₹17.8B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹697.13 – ₹1,058 · fair‑value band ₹406.83 – ₹838.70 · the ₹861.25 price screens above the ₹593.40 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Windlas Biotech Limited (WINDLAS) currently trades at ₹861.25, while our model-based Fair Value estimate is ₹593.40 — implying the stock looks roughly 31.1% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Windlas Biotech Limited generated revenue of ₹9.0B at a net margin of 7.4%. Revenue grew 17.7% year over year. It earns a return on equity of 12.2%. Net debt stands at ₹334M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Windlas Biotech Limited reported revenue of ₹9.0B in FY2026 versus ₹4.6B in FY2022, a compound +18.2%/yr. Reported net income was ₹665M in FY2026, compounding +14.9%/yr from FY2022.
Is WINDLAS fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Windlas Biotech Limited (WINDLAS) undervalued?
What is the fair value of WINDLAS?
What is the quality score of WINDLAS?
What is the revenue of Windlas Biotech Limited (WINDLAS)?
What is the net profit margin of WINDLAS?
Does Windlas Biotech Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.